ClinicalTrials.gg
CompletedNCT04875533Updated Nov 5, 2024Results posted

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan

A Phase 3 interventional study of 20vPnC and Saline in Pneumococcal Disease, sponsored by Pfizer. Completed at 28 sites in 3 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,425
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
5th of 19
1,425 · median 668
Started
2021
with 1 other
Phase 3
14 of 19
1 open now
Registered
9th of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 5th largest by enrollment, is one of 2 that started in 2021, is one of 14 in phase 3, and was the 9th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults 60 years of age and older in Japan, Korea, and Taiwan

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants 60 years of age and older at the time of consent.
  • Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of study intervention. (For adults 60 through 64 years of age to be enrolled at Japan sites: Participants must have a preexisting chronic stable disease with an elevated risk for pneumococcal disease.)

Exclusion criteria

Exclusion criteria:

  • History of microbiologically proven invasive disease caused by S pneumoniae.
  • Serious chronic disorder, including , severe requiring supplemental oxygen, end-stage renal disease with or without dialysis, cirrhosis of the liver, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
  • Previous vaccination with any licensed or pneumococcal vaccine, or planned receipt through study participation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,425 participants (actual)

Study arms

  • Experimental
    20vPnC/Saline

    20vPnC and saline

    Biological: 20vPnC · Other: Saline

  • Active comparator
    13vPnC/PPSV23

    13vPnC and PPSV23

    Biological: 13vPnC · Biological: PPSV23

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Prompted Local Reactions Within 10 Days After Vaccination 1 (20vPnC or 13vPnC)

    Reactions were collected in the e-diary including redness, swelling, and pain at the injection site. Exact 2-sided CI was calculated based on the Clopper and Pearson method. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), and severe (\>10.0 cm). Pain at the injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), and severe (prevents daily activity).

    Time frame: Within 10 days after 20vPnC in the 20vPnC/Saline group or 13vPnC in the 13vPnC/PPSV23 group

  2. Percentage of Participants With Prompted Systemic Events Within 7 Days After Vaccination 1 (20vPnC or 13vPnC)

    Events were collected in the e-diary including fever, headache, fatigue, muscle pain, and joint pain. Exact 2-sided CI was calculated based on the Clopper and Pearson method. Fever was categorized as ≥38.0 degree Celsius (°C), ≥38.0°C to 38.4°C, \>38.4°C to 38.9°C, \>38.9°C to 40.0°C, and \>40.0°C. Fatigue, headache, muscle pain, and joint pain were graded as mild (does not interfere with activity), moderate (some interference with activity), and severe (prevents daily activity).

    Time frame: Within 7 days after 20vPnC in the 20vPnC/Saline group or 13vPnC in the 13vPnC/PPSV23 group

  3. Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination 1 (20vPnC or 13vPnC)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Within 1 month after 20vPnC in the 20vPnC/Saline group or 13vPnC in the 13vPnC/PPSV23 group

  4. Percentage of Participants With Serious Adverse Events (SAEs) Within 1 Month After Vaccination 1 (20vPnC or 13vPnC)

    An SAE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; resulted in congenital anomaly/birth defect or that was considered to be an important medical event.

    Time frame: Within 1 Month After Vaccination 1 (20vPnC or 13vPnC)

  5. Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13-matched Serotypes at 1 Month After Vaccination 1 (20vPnC or 13vPnC)

    OPA titers were determined for the 13 matching pneumococcal serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F. GMTs and 2-sided CIs were calculated by exponentiating the Least Square (LS) means and the corresponding CIs based on analysis of log-transformed OPA titers using a regression model with vaccine group, sex, smoking status, age at vaccination in years (continuous), baseline log-transformed OPA titers, and country.

    Time frame: 1 month after 20vPnC in the 20vPnC/Saline group or 13vPnC in the 13vPnC/PPSV23 group

  6. Pneumococcal OPA GMTs for 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23)

    OPA titers were determined for serotypes: 8, 10A, 11A, 12F, 15B, 22F, and 33F. GMTs and 2-sided CIs were calculated by exponentiating the LS means and the corresponding CIs based on analysis of log-transformed OPA titers using a regression model with vaccine group, sex, smoking status, age at vaccination in years (continuous), baseline log-transformed OPA titers, and country.

    Time frame: 1 month after 20vPnC in the 20vPnC/Saline group or 1 month after PPSV23 in the 13vPnC/PPSV23 group.

Secondary outcomes

  1. OPA Geometric Mean Fold Rise (GMFRs) For 13-matched Serotypes From Before To 1 Month After Vaccination 1 (20vPnC or 13vPnC)

    GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs (based on the Student's t distribution), for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

    Time frame: Before Vaccination 1 to 1 month after 20vPnC in the 20vPnC/saline group or 13vPnC in the 13vPnC/PPSV23 group.

  2. OPA GMFRs for 7 Additional Serotypes From Before to 1 Month After Vaccination 1 (20vPnC) or From Before Vaccination 1 to 1 Month After Vaccination 2 (PPSV23)

    GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs (based on the Student's t distribution), for serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F.

    Time frame: From before Vaccination 1 (20vPnC) to 1 month after Vaccination 1 (20vPnC) in the 20vPnC/Saline group or from before Vaccination 1 (13vPnC) to 1 month after Vaccination 2 (PPSV23) in the 13vPnC/PPSV23 group

  3. Percentage of Participants With ≥4 Fold Rise for 13-matched Serotypes of OPA Titers From Before to 1 Month After Vaccination 1 (20vPnC or 13vPnC)

    The percentage of participants with a ≥4-fold rise in OPA titers and associated 95% CI before vaccination to 1 month after vaccination with 20vPnC or 13vPnC for the 13 matching serotypes, including 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F were summarized.

    Time frame: From before Vaccination 1 to 1 month after 20vPnC in the 20vPnC/Saline group or 13vPnC in the 13vPnC/PPSV23 group

  4. Percentage of Participants With ≥4 Fold Rise in 7 Additional Serotypes of OPA Titers From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC) or From Before Vaccination 1 to 1 Month After Vaccination 2 (PPSV23)

    The percentage of participants with a ≥4-fold rise in OPA titers and associated 95% CI before vaccination to 1 month after vaccination with 20vPnC or PPSV23 for the 7 additional serotypes, including 8, 10A, 11A, 12F, 15B, 22F, and 33F were summarized.

    Time frame: From before Vaccination 1 (20vPnC) to 1 month after Vaccination 1 (20vPnC) in the 20vPnC/Saline group or from before Vaccination 1 (13vPnC) to 1 month after Vaccination 2 (PPSV23) in the 13vPnC/PPSV23 group

  5. Percentage of Participants With 13-matched Serotypes of OPA Titers ≥The Lower Limit of Quantitation (LLOQ) 1 Month After Vaccination 1 (20vPnC or 13vPnC)

    The percentage of participants with OPA titers ≥LLOQ and associated 95% CIs were calculated for the time point 1 month after vaccination with 20vPnC or 13vPnC for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

    Time frame: 1 month after 20vPnC in the 20vPnC/saline group or 13vPnC in the 13vPnC/PPSV23 group

  6. Percentage of Participants With Pneumococcal OPA Titers ≥LLOQ for the 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23)

    The percentage of participants with OPA titers ≥LLOQ and associated 95% CIs were calculated for the time point 1 month after vaccination with 20vPnC in the 20vPnC/saline groups or PPSV23 in the 13vPnC/PPSV23 group for serotypes: 8, 10A, 11A, 12F, 15B, 22F, and 33F.

    Time frame: 1 month after Vaccination 1 (20vPnC) in the 20vPnC/saline group or a month after Vaccination 2 (PPSV23) in the 13vPnC/PPSV23 group

  7. Percentage of Participants With Prompted Local Reactions Within 10 Days After Vaccination 2 (PPSV23 or Saline) in Participants Enrolled at Japan Sites

    Reactions within 10 days after Vaccination 2 (PPSV23 or saline) in participants enrolled at Japan sites were collected in the e-diary including redness, swelling, and pain at the injection site. Exact 2-sided CI was calculated based on the Clopper and Pearson method. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), and severe (\>10.0 cm). Pain at the injection site was grades as mild (does not interfere with activity), moderate (interferes with activity), and severe (prevents daily activity). This endpoint was requested by local Japan regulator.

    Time frame: Within 10 days after saline in 20vPnC/Saline group or PPSV23 in 13vPnC/PPSV23 group

  8. Percentage of Participants With Prompted Systemic Events Within 7 Days After Vaccination 2 (PPSV23 or Saline) in Participants Enrolled at Japan Sites

    Events within 7 days after Vaccination 2 (PPSV23 or saline) in participants enrolled at Japan sites were collected in the e-diary including fever, headache, fatigue, muscle pain, and joint pain. Exact 2-sided CI was calculated based on the Clopper and Pearson method. Fever was categorized as ≥38.0 °C, ≥38.0°C to 38.4°C, \>38.4°C to 38.9°C, \>38.9°C to 40.0°C, and \>40.0°C. Fatigue, headache, muscle pain, and joint pain were grades as mild (does not interfere with activity), moderate (some interference with activity), and severe (prevents daily activity). This endpoint was requested by local Japan regulator.

    Time frame: Within 7 days after saline in 20vPnC/Saline group or PPSV23 in 13vPnC/PPSV23 group

07

Results

Posted Nov 28, 2023

Participant flow

Participants 60 years of age and above were recruited into this study to received either Pneumococcal Conjugate Vaccine (20vPnC)/saline or 13-valent pneumococcal conjugate vaccine (13vPnC)/23-valent pneumococcal polysaccharide vaccine (PPSV23).

Participant flow — Overall Study
Milestone20vPnC/Saline13vPnC/PPSV23
Started711710
Vaccinated with vaccination 2695699
Completed692699
Not completed1911
Withdrew: Adverse event64
Withdrew: Protocol violation40
Withdrew: Withdrawal by subject85
Withdrew: No longer meets eligibility criteria10
Withdrew: Other02

Outcome measures

PrimaryPercentage of Participants With Prompted Local Reactions Within 10 Days After Vaccination 1 (20vPnC or 13vPnC)

Reactions were collected in the e-diary including redness, swelling, and pain at the injection site. Exact 2-sided CI was calculated based on the Clopper and Pearson method. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), and severe (\>10.0 cm). Pain at the injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), and severe (prevents daily activity).

Time frame:
Within 10 days after 20vPnC in the 20vPnC/Saline group or 13vPnC in the 13vPnC/PPSV23 group
Reported as:
Number · percentage of participants
Percentage of Participants With Prompted Local Reactions Within 10 Days After Vaccination 1 (20vPnC or 13vPnC)
percentage of participants20vPnC/Saline13vPnC/PPSV23
Redness-Any12.4 (10.1 to 15.0)9.7 (7.6 to 12.1)
Redness-Mild6.2 (4.5 to 8.2)4.5 (3.1 to 6.3)
Redness-Moderate4.8 (3.3 to 6.6)3.9 (2.6 to 5.6)
Redness-Severe1.4 (0.7 to 2.6)1.3 (0.6 to 2.4)
Swelling-Any10.4 (8.3 to 12.9)7.5 (5.6 to 9.7)
Swelling-Mild5.4 (3.8 to 7.3)3.5 (2.3 to 5.2)
Swelling-Moderate4.5 (3.1 to 6.3)3.1 (2.0 to 4.7)
Swelling-Severe0.6 (0.2 to 1.4)0.8 (0.3 to 1.8)
Pain at the injection site-Any52.3 (48.5 to 56.0)50.7 (47.0 to 54.4)
Pain at the injection site-Mild45.6 (41.9 to 49.4)46.3 (42.6 to 50.1)
Pain at the injection site-Moderate6.5 (4.8 to 8.5)4.1 (2.8 to 5.8)
Pain at the injection site-Severe0.1 (0.0 to 0.8)0.3 (0.0 to 1.0)
PrimaryPercentage of Participants With Prompted Systemic Events Within 7 Days After Vaccination 1 (20vPnC or 13vPnC)

Events were collected in the e-diary including fever, headache, fatigue, muscle pain, and joint pain. Exact 2-sided CI was calculated based on the Clopper and Pearson method. Fever was categorized as ≥38.0 degree Celsius (°C), ≥38.0°C to 38.4°C, \>38.4°C to 38.9°C, \>38.9°C to 40.0°C, and \>40.0°C. Fatigue, headache, muscle pain, and joint pain were graded as mild (does not interfere with activity), moderate (some interference with activity), and severe (prevents daily activity).

Time frame:
Within 7 days after 20vPnC in the 20vPnC/Saline group or 13vPnC in the 13vPnC/PPSV23 group
Reported as:
Number · percentage of participants
Percentage of Participants With Prompted Systemic Events Within 7 Days After Vaccination 1 (20vPnC or 13vPnC)
percentage of participants20vPnC/Saline13vPnC/PPSV23
Fever ≥38.0°C0.1 (0.0 to 0.8)0.6 (0.2 to 1.4)
Fever ≥38.0°C to 38.4°C0.1 (0.0 to 0.8)0.3 (0.0 to 1.0)
Fever >38.4°C to 38.9°C0 (0.0 to 0.5)0.1 (0.0 to 0.8)
Fever >38.9°C to 40.0°C0 (0.0 to 0.5)0.1 (0.0 to 0.8)
Fever >40.0°C0 (0.0 to 0.5)0 (0.0 to 0.5)
Fatigue-Any20.7 (17.8 to 23.9)23.0 (19.9 to 26.2)
Fatigue-Mild18.0 (15.3 to 21.1)18.9 (16.1 to 21.9)
Fatigue-Moderate2.7 (1.6 to 4.1)3.8 (2.5 to 5.5)
Fatigue-Severe0 (0.0 to 0.5)0.3 (0.0 to 1.0)
Headache-Any9.2 (7.1 to 11.5)11.0 (8.8 to 13.5)
Headache-Mild8.2 (6.3 to 10.4)9.6 (7.5 to 12.0)
Headache-Moderate1.0 (0.4 to 2.0)1.1 (0.5 to 2.2)
Headache-Severe0 (0.0 to 0.5)0.3 (0.0 to 1.0)
Muscle pain-Any17.6 (14.9 to 20.6)17.9 (15.1 to 20.9)
Muscle pain-Mild15.2 (12.6 to 18.1)14.8 (12.3 to 17.6)
Muscle pain-Moderate2.3 (1.3 to 3.6)3.0 (1.8 to 4.5)
Muscle pain-Severe0.1 (0.0 to 0.8)0.1 (0.0 to 0.8)
Joint pain-Any6.8 (5.0 to 8.9)7.9 (6.0 to 10.1)
Joint pain-Mild5.2 (3.7 to 7.1)5.9 (4.3 to 7.9)
Joint pain-Moderate1.5 (0.8 to 2.8)2.0 (1.1 to 3.3)
Joint pain-Severe0 (0.0 to 0.5)0 (0.0 to 0.5)
PrimaryPercentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination 1 (20vPnC or 13vPnC)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Within 1 month after 20vPnC in the 20vPnC/Saline group or 13vPnC in the 13vPnC/PPSV23 group
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination 1 (20vPnC or 13vPnC)
percentage of participants20vPnC/Saline13vPnC/PPSV23
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination 1 (20vPnC or 13vPnC)5.6 (4.0 to 7.6)5.9 (4.3 to 7.9)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) Within 1 Month After Vaccination 1 (20vPnC or 13vPnC)

An SAE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; resulted in congenital anomaly/birth defect or that was considered to be an important medical event.

Time frame:
Within 1 Month After Vaccination 1 (20vPnC or 13vPnC)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) Within 1 Month After Vaccination 1 (20vPnC or 13vPnC)
percentage of participants20vPnC/Saline13vPnC/PPSV23
Percentage of Participants With Serious Adverse Events (SAEs) Within 1 Month After Vaccination 1 (20vPnC or 13vPnC)0.4 (0.1 to 1.2)0.6 (0.2 to 1.4)
PrimaryPneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13-matched Serotypes at 1 Month After Vaccination 1 (20vPnC or 13vPnC)

OPA titers were determined for the 13 matching pneumococcal serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F. GMTs and 2-sided CIs were calculated by exponentiating the Least Square (LS) means and the corresponding CIs based on analysis of log-transformed OPA titers using a regression model with vaccine group, sex, smoking status, age at vaccination in years (continuous), baseline log-transformed OPA titers, and country.

Time frame:
1 month after 20vPnC in the 20vPnC/Saline group or 13vPnC in the 13vPnC/PPSV23 group
Reported as:
Geometric mean · titer
Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13-matched Serotypes at 1 Month After Vaccination 1 (20vPnC or 13vPnC)
titer20vPnC/Saline13vPnC/PPSV23
Serotype 1207 (177 to 242)267 (229 to 311)
Serotype 350 (45 to 55)56 (50 to 62)
Serotype 4813 (696 to 949)1029 (881 to 1202)
Serotype 596 (82 to 112)125 (107 to 145)
Serotype 6A1286 (1088 to 1520)1475 (1249 to 1742)
Serotype 6B1399 (1196 to 1637)1537 (1314 to 1798)
Serotype 7F1735 (1578 to 1907)2076 (1889 to 2282)
Serotype 9V1467 (1285 to 1674)1663 (1459 to 1895)
Serotype 14704 (602 to 824)647 (554 to 756)
Serotype 18C1325 (1142 to 1538)1826 (1575 to 2117)
Serotype 19A864 (750 to 994)1172 (1018 to 1349)
Serotype 19F365 (310 to 431)574 (487 to 676)
Serotype 23F290 (239 to 351)361 (298 to 437)
Statistical analysis
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/13vpnc): 0.78 · 95% CI 0.66 to 0.92
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/13vpnc): 0.89 · 95% CI 0.79 to 0.99
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/13vpnc): 0.79 · 95% CI 0.67 to 0.94
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/13vpnc): 0.77 · 95% CI 0.65 to 0.91
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/13vpnc): 0.87 · 95% CI 0.73 to 1.05
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/13vpnc): 0.91 · 95% CI 0.77 to 1.08
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/13vpnc): 0.84 · 95% CI 0.75 to 0.93
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/13vpnc): 0.88 · 95% CI 0.76 to 1.02
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/13vpnc): 1.09 · 95% CI 0.92 to 1.29
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/13vpnc): 0.73 · 95% CI 0.62 to 0.85
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/13vpnc): 0.74 · 95% CI 0.63 to 0.86
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/13vpnc): 0.64 · 95% CI 0.53 to 0.76
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/13vpnc): 0.80 · 95% CI 0.65 to 0.99
PrimaryPneumococcal OPA GMTs for 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23)

OPA titers were determined for serotypes: 8, 10A, 11A, 12F, 15B, 22F, and 33F. GMTs and 2-sided CIs were calculated by exponentiating the LS means and the corresponding CIs based on analysis of log-transformed OPA titers using a regression model with vaccine group, sex, smoking status, age at vaccination in years (continuous), baseline log-transformed OPA titers, and country.

Time frame:
1 month after 20vPnC in the 20vPnC/Saline group or 1 month after PPSV23 in the 13vPnC/PPSV23 group.
Reported as:
Geometric mean · titer
Pneumococcal OPA GMTs for 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23)
titer20vPnC/Saline13vPnC/PPSV23
Serotype 8561 (490 to 642)971 (850 to 1110)
Serotype 10A1661 (1422 to 1939)777 (667 to 906)
Serotype 11A3331 (2834 to 3913)1933 (1644 to 2274)
Serotype 12F3543 (2976 to 4217)2104 (1766 to 2507)
Serotype 15B1265 (1039 to 1539)593 (487 to 723)
Serotype 22F2818 (2345 to 3388)1737 (1445 to 2089)
Serotype 33F6675 (5751 to 7748)5853 (5046 to 6788)
Statistical analysis
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/ppsv23): 0.58 · 95% CI 0.50 to 0.67
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/ppsv23): 2.14 · 95% CI 1.80 to 2.53
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/ppsv23): 1.72 · 95% CI 1.44 to 2.06
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/ppsv23): 1.68 · 95% CI 1.39 to 2.04
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/ppsv23): 2.13 · 95% CI 1.72 to 2.64
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/ppsv23): 1.62 · 95% CI 1.33 to 1.98
  • 20vPnC/Saline vs 13vPnC/PPSV23 · Ratio of gmts (20vpnc/ppsv23): 1.14 · 95% CI 0.97 to 1.34
SecondaryOPA Geometric Mean Fold Rise (GMFRs) For 13-matched Serotypes From Before To 1 Month After Vaccination 1 (20vPnC or 13vPnC)

GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs (based on the Student's t distribution), for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

Time frame:
Before Vaccination 1 to 1 month after 20vPnC in the 20vPnC/saline group or 13vPnC in the 13vPnC/PPSV23 group.
Reported as:
Geometric mean · fold rise
OPA Geometric Mean Fold Rise (GMFRs) For 13-matched Serotypes From Before To 1 Month After Vaccination 1 (20vPnC or 13vPnC)
fold rise20vPnC/Saline13vPnC/PPSV23
Serotype 113.1 (11.5 to 14.9)16.3 (14.2 to 18.7)
Serotype 34.8 (4.4 to 5.3)5.4 (4.9 to 5.9)
Serotype 430.1 (26.0 to 34.9)35.7 (30.5 to 41.7)
Serotype 55.4 (4.8 to 6.0)6.9 (6.1 to 7.8)
Serotype 6A24.3 (20.9 to 28.3)26.9 (23.0 to 31.6)
Serotype 6B14.8 (12.8 to 17.3)15.7 (13.5 to 18.4)
Serotype 7F5.9 (5.3 to 6.6)7.0 (6.3 to 7.9)
Serotype 9V7.1 (6.3 to 8.0)7.5 (6.6 to 8.5)
Serotype 148.7 (7.6 to 10.0)7.8 (6.7 to 9.0)
Serotype 18C18.6 (16.0 to 21.5)24.6 (21.3 to 28.5)
Serotype 19A24.1 (20.9 to 27.8)30.2 (26.2 to 34.8)
Serotype 19F8.9 (7.8 to 10.2)13.5 (11.7 to 15.6)
Serotype 23F18.7 (15.9 to 22.0)22.2 (18.8 to 26.2)
SecondaryOPA GMFRs for 7 Additional Serotypes From Before to 1 Month After Vaccination 1 (20vPnC) or From Before Vaccination 1 to 1 Month After Vaccination 2 (PPSV23)

GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs (based on the Student's t distribution), for serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F.

Time frame:
From before Vaccination 1 (20vPnC) to 1 month after Vaccination 1 (20vPnC) in the 20vPnC/Saline group or from before Vaccination 1 (13vPnC) to 1 month after Vaccination 2 (PPSV23) in the 13vPnC/PPSV23 group
Reported as:
Geometric mean · fold rise
OPA GMFRs for 7 Additional Serotypes From Before to 1 Month After Vaccination 1 (20vPnC) or From Before Vaccination 1 to 1 Month After Vaccination 2 (PPSV23)
fold rise20vPnC/Saline13vPnC/PPSV23
Serotype 817.9 (15.7 to 20.3)30.2 (26.5 to 34.4)
Serotype 10A13.1 (11.4 to 15.1)6.1 (5.4 to 7.0)
Serotype 11A14.5 (12.2 to 17.1)7.3 (6.2 to 8.5)
Serotype 12F69.1 (58.9 to 81.1)38.2 (32.2 to 45.3)
Serotype 15B25.9 (21.7 to 31.0)11.8 (10.0 to 14.0)
Serotype 22F41.1 (33.4 to 50.5)23.1 (19.2 to 27.9)
Serotype 33F7.5 (6.5 to 8.5)6.2 (5.5 to 7.1)
SecondaryPercentage of Participants With ≥4 Fold Rise for 13-matched Serotypes of OPA Titers From Before to 1 Month After Vaccination 1 (20vPnC or 13vPnC)

The percentage of participants with a ≥4-fold rise in OPA titers and associated 95% CI before vaccination to 1 month after vaccination with 20vPnC or 13vPnC for the 13 matching serotypes, including 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F were summarized.

Time frame:
From before Vaccination 1 to 1 month after 20vPnC in the 20vPnC/Saline group or 13vPnC in the 13vPnC/PPSV23 group
Reported as:
Number · percentage of participants
Percentage of Participants With ≥4 Fold Rise for 13-matched Serotypes of OPA Titers From Before to 1 Month After Vaccination 1 (20vPnC or 13vPnC)
percentage of participants20vPnC/Saline13vPnC/PPSV23
Serotype 172.6 (69.0 to 75.9)74.2 (70.8 to 77.4)
Serotype 357.6 (53.8 to 61.4)59.4 (55.5 to 63.1)
Serotype 480.1 (76.8 to 83.1)79.6 (76.3 to 82.6)
Serotype 554.9 (51.1 to 58.7)59.6 (55.8 to 63.3)
Serotype 6A78.9 (75.6 to 81.9)77.6 (74.3 to 80.7)
Serotype 6B71.2 (67.5 to 74.7)70.6 (66.9 to 74.2)
Serotype 7F55.7 (51.8 to 59.6)61.9 (58.0 to 65.7)
Serotype 9V60.5 (56.6 to 64.3)62.8 (59.0 to 66.5)
Serotype 1459.5 (55.6 to 63.3)53.4 (49.5 to 57.3)
Serotype 18C73.3 (69.8 to 76.6)79.1 (75.9 to 82.1)
Serotype 19A79.6 (76.3 to 82.5)82.4 (79.3 to 85.2)
Serotype 19F62.5 (58.7 to 66.1)69.9 (66.3 to 73.4)
Serotype 23F69.8 (66.2 to 73.2)72.5 (69.0 to 75.8)
SecondaryPercentage of Participants With ≥4 Fold Rise in 7 Additional Serotypes of OPA Titers From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC) or From Before Vaccination 1 to 1 Month After Vaccination 2 (PPSV23)

The percentage of participants with a ≥4-fold rise in OPA titers and associated 95% CI before vaccination to 1 month after vaccination with 20vPnC or PPSV23 for the 7 additional serotypes, including 8, 10A, 11A, 12F, 15B, 22F, and 33F were summarized.

Time frame:
From before Vaccination 1 (20vPnC) to 1 month after Vaccination 1 (20vPnC) in the 20vPnC/Saline group or from before Vaccination 1 (13vPnC) to 1 month after Vaccination 2 (PPSV23) in the 13vPnC/PPSV23 group
Reported as:
Number · percentage of participants
Percentage of Participants With ≥4 Fold Rise in 7 Additional Serotypes of OPA Titers From Before Vaccination 1 to 1 Month After Vaccination 1 (20vPnC) or From Before Vaccination 1 to 1 Month After Vaccination 2 (PPSV23)
percentage of participants20vPnC/Saline13vPnC/PPSV23
Serotype 880.5 (77.3 to 83.4)86.3 (83.5 to 88.8)
Serotype 10A70.2 (66.5 to 73.7)56.1 (52.1 to 60.0)
Serotype 11A69.4 (65.5 to 73.2)53.1 (48.8 to 57.3)
Serotype 12F86.9 (84.0 to 89.5)80.7 (77.3 to 83.8)
Serotype 15B73.6 (70.0 to 77.0)59.7 (55.7 to 63.5)
Serotype 22F75.5 (71.9 to 78.8)70.8 (67.0 to 74.4)
Serotype 33F61.1 (57.2 to 64.9)58.1 (54.1 to 62.0)
SecondaryPercentage of Participants With 13-matched Serotypes of OPA Titers ≥The Lower Limit of Quantitation (LLOQ) 1 Month After Vaccination 1 (20vPnC or 13vPnC)

The percentage of participants with OPA titers ≥LLOQ and associated 95% CIs were calculated for the time point 1 month after vaccination with 20vPnC or 13vPnC for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

Time frame:
1 month after 20vPnC in the 20vPnC/saline group or 13vPnC in the 13vPnC/PPSV23 group
Reported as:
Number · percentage of participants
Percentage of Participants With 13-matched Serotypes of OPA Titers ≥The Lower Limit of Quantitation (LLOQ) 1 Month After Vaccination 1 (20vPnC or 13vPnC)
percentage of participants20vPnC/Saline13vPnC/PPSV23
Serotype 184.3 (81.3 to 86.9)85.6 (82.8 to 88.1)
Serotype 382.3 (79.2 to 85.1)82.4 (79.3 to 85.2)
Serotype 491.7 (89.4 to 93.7)92.4 (90.1 to 94.2)
Serotype 567.6 (63.9 to 71.1)70.7 (67.2 to 74.1)
Serotype 6A89.8 (87.3 to 91.9)88.8 (86.2 to 91.1)
Serotype 6B91.5 (89.1 to 93.5)90.2 (87.7 to 92.4)
Serotype 7F98.1 (96.8 to 99.0)98.0 (96.6 to 98.9)
Serotype 9V87.2 (84.5 to 89.6)88.3 (85.6 to 90.6)
Serotype 1492.1 (89.8 to 94.0)88.4 (85.7 to 90.7)
Serotype 18C93.3 (91.2 to 95.1)94.8 (92.8 to 96.3)
Serotype 19A95.0 (93.1 to 96.5)96.8 (95.2 to 98.0)
Serotype 19F76.4 (73.0 to 79.5)82.3 (79.2 to 85.1)
Serotype 23F79.8 (76.6 to 82.7)82.4 (79.3 to 85.2)
SecondaryPercentage of Participants With Pneumococcal OPA Titers ≥LLOQ for the 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23)

The percentage of participants with OPA titers ≥LLOQ and associated 95% CIs were calculated for the time point 1 month after vaccination with 20vPnC in the 20vPnC/saline groups or PPSV23 in the 13vPnC/PPSV23 group for serotypes: 8, 10A, 11A, 12F, 15B, 22F, and 33F.

Time frame:
1 month after Vaccination 1 (20vPnC) in the 20vPnC/saline group or a month after Vaccination 2 (PPSV23) in the 13vPnC/PPSV23 group
Reported as:
Number · percentage of participants
Percentage of Participants With Pneumococcal OPA Titers ≥LLOQ for the 7 Additional Serotypes at 1 Month After Vaccination 1 (20vPnC) or 1 Month After Vaccination 2 (PPSV23)
percentage of participants20vPnC/Saline13vPnC/PPSV23
Serotype 895.2 (93.3 to 96.7)96.7 (95.1 to 97.9)
Serotype 10A91.1 (88.7 to 93.2)82.1 (78.9 to 84.9)
Serotype 11A96.9 (95.3 to 98.1)92.3 (90.0 to 94.3)
Serotype 12F96.9 (95.3 to 98.1)91.7 (89.3 to 93.7)
Serotype 15B90.2 (87.6 to 92.4)80.3 (77.1 to 83.3)
Serotype 22F96.5 (94.8 to 97.8)93.3 (91.1 to 95.1)
Serotype 33F97.4 (95.9 to 98.5)96.5 (94.8 to 97.8)
SecondaryPercentage of Participants With Prompted Local Reactions Within 10 Days After Vaccination 2 (PPSV23 or Saline) in Participants Enrolled at Japan Sites

Reactions within 10 days after Vaccination 2 (PPSV23 or saline) in participants enrolled at Japan sites were collected in the e-diary including redness, swelling, and pain at the injection site. Exact 2-sided CI was calculated based on the Clopper and Pearson method. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), and severe (\>10.0 cm). Pain at the injection site was grades as mild (does not interfere with activity), moderate (interferes with activity), and severe (prevents daily activity). This endpoint was requested by local Japan regulator.

Time frame:
Within 10 days after saline in 20vPnC/Saline group or PPSV23 in 13vPnC/PPSV23 group
Reported as:
Number · percentage of participants
Percentage of Participants With Prompted Local Reactions Within 10 Days After Vaccination 2 (PPSV23 or Saline) in Participants Enrolled at Japan Sites
percentage of participants20vPnC/Saline13vPnC/PPSV23
Redness-Any1.2 (0.4 to 2.8)17.2 (13.7 to 21.2)
Redness-Mild1.2 (0.4 to 2.8)3.6 (2.0 to 5.9)
Redness-Moderate0 (0 to 0.9)8.2 (5.8 to 11.3)
Redness-Severe0 (0 to 0.9)5.3 (3.4 to 8.0)
Swelling-Any1.0 (0.3 to 2.5)28.3 (24.0 to 32.9)
Swelling-Mild1.0 (0.3 to 2.5)7.7 (5.4 to 10.8)
Swelling-Moderate0 (0 to 0.9)13.6 (10.4 to 17.2)
Swelling-Severe0 (0 to 0.9)7.0 (4.8 to 9.9)
Pain at the injection site-Any5.6 (3.6 to 8.3)73.1 (68.6 to 77.3)
Pain at the injection site-Mild5.6 (3.6 to 8.3)46.0 (41.1 to 50.9)
Pain at the injection site-Moderate0 (0.0 to 0.9)24.5 (20.4 to 28.9)
Pain at the injection site-Severe0 (0.0 to 0.9)2.7 (1.3 to 4.7)
SecondaryPercentage of Participants With Prompted Systemic Events Within 7 Days After Vaccination 2 (PPSV23 or Saline) in Participants Enrolled at Japan Sites

Events within 7 days after Vaccination 2 (PPSV23 or saline) in participants enrolled at Japan sites were collected in the e-diary including fever, headache, fatigue, muscle pain, and joint pain. Exact 2-sided CI was calculated based on the Clopper and Pearson method. Fever was categorized as ≥38.0 °C, ≥38.0°C to 38.4°C, \>38.4°C to 38.9°C, \>38.9°C to 40.0°C, and \>40.0°C. Fatigue, headache, muscle pain, and joint pain were grades as mild (does not interfere with activity), moderate (some interference with activity), and severe (prevents daily activity). This endpoint was requested by local Japan regulator.

Time frame:
Within 7 days after saline in 20vPnC/Saline group or PPSV23 in 13vPnC/PPSV23 group
Reported as:
Number · percentage of participants
Percentage of Participants With Prompted Systemic Events Within 7 Days After Vaccination 2 (PPSV23 or Saline) in Participants Enrolled at Japan Sites
percentage of participants20vPnC/Saline13vPnC/PPSV23
Fever ≥38.0°C0.2 (0.0 to 1.4)1.7 (0.7 to 3.5)
Fever ≥38.0°C to 38.4°C0 (0.0 to 0.9)1.5 (0.5 to 3.1)
Fever >38.4°C to 38.9°C0.2 (0.0 to 1.4)0.2 (0.0 to 1.3)
Fever >38.9°C to 40.0°C0 (0.0 to 0.9)0 (0.0 to 0.9)
Fever >40.0°C0 (0.0 to 0.9)0 (0.0 to 0.9)
Fatigue-Any9.5 (6.9 to 12.8)22.5 (18.6 to 26.9)
Fatigue-Mild7.8 (5.4 to 10.9)15.7 (12.4 to 19.6)
Fatigue-Moderate1.5 (0.5 to 3.2)6.1 (4.0 to 8.8)
Fatigue-Severe0.2 (0.0 to 1.4)0.7 (0.2 to 2.1)
Headache-Any4.9 (3.0 to 7.5)9.4 (6.8 to 12.7)
Headache-Mild4.4 (2.6 to 6.9)8.0 (5.6 to 11.0)
Headache-Moderate0.5 (0.1 to 1.8)1.2 (0.4 to 2.8)
Headache-Severe0 (0.0 to 0.9)0.2 (0.0 to 1.3)
Muscle pain-Any4.2 (2.4 to 6.6)25.4 (21.3 to 29.9)
Muscle pain-Mild3.7 (2.1 to 6.0)16.5 (13.0 to 20.4)
Muscle pain-Moderate0.5 (0.1 to 1.8)8.0 (5.6 to 11.0)
Muscle pain-Severe0 (0.0 to 0.9)1.0 (0.3 to 2.5)
Joint pain-Any1.7 (0.7 to 3.5)6.1 (4.0 to 8.8)
Joint pain-Mild1.5 (0.5 to 3.2)4.4 (2.6 to 6.8)
Joint pain-Moderate0.2 (0.0 to 1.4)1.5 (0.5 to 3.1)
Joint pain-Severe0 (0.0 to 0.9)0.2 (0.0 to 1.3)

Adverse events

Collected over SAEs, non-serious AEs (NSAEs), and deaths were reported from Vaccination 1 (Day 1) to 28-42 days after Vaccination 1 and Vaccination 2 to 28-42 days after Vaccination 2 from all participants. The e-diary was collected 10 days for local reactions and 7 days for systemic events after Vaccination 1 for all participants, and after Vaccination 2 for Japan participants only.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
20vPnC/Saline (Vaccination 1)0/711 (0%)3/711 (0.4%)448/711 (63%)
13vPnC/PPSV23 (Vaccination 1)0/710 (0%)4/710 (0.6%)439/710 (61.8%)
20vPnC/Saline (Vaccination 2)0/695 (0%)4/695 (0.6%)78/695 (11.2%)
13vPnC/PPSV23 (Vaccination 2)0/699 (0%)3/699 (0.4%)333/699 (47.6%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
Event20vPnC/Saline (Vaccination 1)13vPnC/PPSV23 (Vaccination 1)20vPnC/Saline (Vaccination 2)13vPnC/PPSV23 (Vaccination 2)
COVID-19Infections and infestations1/7111/7102/6951/699
Myocardial infarctionCardiac disorders0/7110/7101/6950/699
Pneumonia bacterialInfections and infestations0/7110/7101/6950/699
Cerebral infarctionNervous system disorders0/7110/7101/6950/699
PneumothoraxRespiratory, thoracic and mediastinal disorders0/7110/7101/6950/699
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/7110/7101/6950/699
Deep vein thrombosisVascular disorders0/7110/7101/6950/699
Atrial fibrillationCardiac disorders0/7110/7100/6951/699
Inguinal herniaGastrointestinal disorders0/7110/7100/6951/699
PyrexiaGeneral disorders0/7111/7100/6950/699
Most frequent other events
Most frequent other events
Event20vPnC/Saline (Vaccination 1)13vPnC/PPSV23 (Vaccination 1)20vPnC/Saline (Vaccination 2)13vPnC/PPSV23 (Vaccination 2)
Injection site pain (PAIN)General disorders371/711360/71023/695302/699
Fatigue (FATIGUE)General disorders147/711163/71039/69593/699
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders125/711127/71017/695105/699
Injection site swelling (SWELLING)General disorders74/71153/7104/695117/699
Injection site erythema (REDNESS)General disorders88/71169/7105/69571/699
Headache (HEADACHE)Nervous system disorders65/71178/71020/69539/699
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders48/71156/7100/6950/699

Baseline characteristics

All participants who receive at least 1 dose of the study intervention (20vPnC, 13vPnC, PPSV23 or saline).

Age, Continuous
Age, Continuous(Years)20vPnC/Saline13vPnC/PPSV23Total
Mean66.0 ± 4.4666.2 ± 4.8366.1 ± 4.65
Age, Customized
Age, Customized(Participants)20vPnC/Saline13vPnC/PPSV23Total
60 to 64 years314314628
65 to 74 years366353719
≥75 years314374
Sex: Female, Male
Sex: Female, Male(Participants)20vPnC/Saline13vPnC/PPSV23Total
Female315315630
Male396395791
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)20vPnC/Saline13vPnC/PPSV23Total
Hispanic or Latino000
Not Hispanic or Latino7117101421
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)20vPnC/Saline13vPnC/PPSV23Total
American Indian or Alaska Native000
Asian7117101421
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

28 sites
  • Seishinkai Inoue Hospital
    Itoshima, Fukuoka 819-1104, Japan
  • Women's Clinic LUNA NEXT STAGE
    Naka-ku, Yokohama-Shi, Kanagawa 231-0861, Japan
  • Medical Corporation Heishinkai OPHAC Hospital
    Osaka-shi, Osaka 532-0003, Japan
  • Medical Corporation Heishinkai OCROM Clinic
    Suita-shi, Osaka 565-0853, Japan
  • Nihonbashi Sakura Clinic
    Chuo-ku, Tokyo 103-0025, Japan
  • Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • P-one Clinic, Keikokai Medical Corporation
    Hachioji-shi, Tokyo 1920071, Japan
  • Hillside Clinic Jingumae
    Shibuya-ku, Tokyo 1500001, Japan
  • Medical Corporation Heishinkai ToCROM Clinic
    Shinjuku-ku, Tokyo 160-0008, Japan
  • SOUSEIKAI PS Clinic
    Fukuoka, 812-0025, Japan
  • Korea University Ansan Hospital
    Ansan-si, Gyeonggi-do 15355, Korea, Republic of
  • The Catholic University of Korea, St. Vincent's Hospital
    Suwon-si, Gyeonggi-do 16247, Korea, Republic of
  • Ajou University Hospital
    Suwon, Gyeonggi-do 16499, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, Seoul-teukbyeolsi [seoul] 08308, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, 41944, Korea, Republic of
  • Inha University Hospital
    Incheon, 22332, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Kangdong Sacred Heart Hospital
    Seoul, 05355, Korea, Republic of
  • Asan medical Center
    Seoul, 05505, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Hallym University Kangnam Sacred Heart Hospital
    Seoul, 07441, Korea, Republic of
  • Ewha Womans University Mokdong Hospital
    Seoul, 07985, Korea, Republic of
  • Far Eastern Memorial Hospital
    New Taipei City,, 220, Taiwan
  • Taipei Medical University Shuang Ho Hospital
    New Taipei City, 23561, Taiwan
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Linkou Chang Gung Memorial Hospital
    Taoyuan City, 333, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in May 2022, 10 months.

Results were first posted in Nov 2023, 1 year 6 months after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 10 months is below that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2021
First posted
May 6, 2021
StartActual
Jun 14, 2021
Primary completionActual
May 13, 2022
CompletionActual
May 13, 2022
Results first posted
Nov 28, 2023
Last update
Nov 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04875533
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 6, 2021
Start date
Jun 14, 2021
Primary completion
May 13, 2022
Completion
May 13, 2022
Results posted
Nov 28, 2023
Last update
Nov 5, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion